By vgreene, 11 March, 2021 Azithromycin in patients admitted to hospital with COVID 19 RECOVERY a randomised controlled open label platform trial
By vgreene, 11 March, 2021 Study considerations open label RCT large sample size N 2 265 incl pts w suspected dz w in 14 days of sx onset only 31 pts had confirmed SARS CoV 2 PCR results incl pts 50y w comorbidities or 65y primary outcome revised during trial recovery was self repo
By vgreene, 11 March, 2021 KEY FINDINGS AZ doesn t reduce hospitalization risk or time to recovery in older adult pts in the community w suspected COVID 19 risk
By vgreene, 11 March, 2021 Azithromycin for community treatment of suspected COVID 19 in people at increased risk of an adverse clinical course in the UK PRINCIPLE a randomised controlled open label adaptive platform trial
By vgreene, 11 March, 2021 Ivermectin Shows Clinical Benefits in Mild to Moderate COVID19 A Randomised Controlled Double blind Dose response Study in Lagos QJM article
By vgreene, 11 March, 2021 Role of Ivermectin in the Prevention of SARS CoV 2 Infection Among Healthcare Workers in India A Matched Case Control Study PLoS One article
By vgreene, 11 March, 2021 Effectiveness of Ivermectin in SARS CoV 2 COVID 19 Patients Int J Sci article
By vgreene, 11 March, 2021 Ivermectin Treatment May Improve the Prognosis of Patients With COVID 19 Arch Bronconeumol article
